EGFR has been shown to support tumorigenicity primarily through signaling toward downstream targets including RAS/RAF/MAPK and PI3-K/AKT pathways, which in turn leads to increased proliferation, angiogenesis, migration and invasion of glioma cells [189,193]. The gene discussed is AKT1; the disease is central nervous system cancer.